Oslo University Hospital, The Norwegian Radium Hospital
Norway's national cancer hospital and research institute, where the alpha emitter radium-223 (Xofigo) and Photocure's bladder imaging agent were born.
Overview
The Norwegian Radium Hospital opened in 1932 as Norway's specialist cancer hospital and became part of Oslo University Hospital in 2009; its Institute for Cancer Research dates from 1954 and is a European reference for cancer genomics, immunology and radiation biology. Roy Larsen and Øyvind Bruland developed radium-223 there and founded Algeta, whose Xofigo became the first approved targeted alpha therapy after Bayer's acquisition, and the hospital also spun out Photocure and Ultimovacs. Current groups include Johanna Olweus on T-cell receptor therapies, Ragnhild Lothe on colorectal genomics, Ola Myklebost on sarcoma and Åslaug Helland, who leads the national IMPRESS-Norway precision medicine trial. The campus is being rebuilt with a new clinic and Norway's first proton therapy centre, and it anchors the Oslo Cancer Cluster innovation park.
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-22.
Matched to Oslo University Hospital, including child institutions. 993 works · 13,190 citations · 82% open access · 10% clinical trials · 3% reviews.
- Marianne G. Guren56 works
- Knut Jørgen Labori54 works
- Michael Bretthauer53 works
- Bjørn Edwin51 works
- Dyre Berg Kleive50 works
- Marc G. Besselink49 works
- Cecilie Essholt Kiserud42 works
- Yuichi Mori40 works
- Bergþór Björnsson39 works
- Mette Kalager38 works
- Institute for Cancer Research
- Targeted alpha therapy heritage (radium-223)
- IMPRESS-Norway precision medicine
- Sarcoma and rare cancers
- Proton therapy centre
Similar pages
not linked directly; found by shared links- InstitutionSahlgrenska University Hospital / Sahlgrenska Center for Cancer Research
Shares Karolinska University Hospital, Radioligand therapy (beta emitters).
- InstitutionUppsala University Hospital / Uppsala University
Shares Karolinska University Hospital, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionQST Hospital (National Institutes for Quantum Science and Technology)
Shares Alpha vs beta emitters, Targeted alpha therapy, Prostate cancer.
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Alpha vs beta emitters, Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- TermRelative biological effectiveness (RBE)
Shares Alpha vs beta emitters, Targeted alpha therapy, Radioligand therapy (beta emitters).
- Key paperRadiopharmaceutical therapy in cancer: clinical advances and challenges
Shares Radium-223, Targeted alpha therapy, Radioligand therapy (beta emitters).
- AgentRadium-223 dichloride
Shares Bayer, Alpha vs beta emitters, Radium-223, Targeted alpha therapy.